Navigation Links
Safety Concerns Prompt Prime to Remove Avandia(R) from Formulary
Date:12/6/2007

ST. PAUL, Minn., Dec. 6 /PRNewswire/ -- Pharmacy benefit manager Prime Therapeutics (Prime) recently announced the removal of the prescription drug Avandia(R) from its national formulary. After careful examination of clinical literature regarding the safety and efficacy of Avandia, Prime's National Pharmacy and Therapeutics (P&T) Committee has made the decision to remove the drug from its formulary. Prime's P&T Committee is a panel of pharmacists and physicians that meets quarterly and reviews drugs for Prime's formulary.

In May 2007, a meta-analysis by Nissen, et al, suggested that Avandia significantly increased the risk of heart attack. The results of this meta-analysis were also duplicated by the Food and Drug Administration (FDA) and Avandia manufacturer, GlaxoSmithKline. Consequently, in November 2007, the FDA announced that a black boxed warning for an increased risk for heart attacks in some patients would be added to Avandia's prescribing information.

Following the May publication of the Avandia meta-analysis, Prime's outcome clinicians began an in-depth analysis of Avandia utilization. An analysis of medical and pharmacy claims revealed that over 25 percent of patients on Avandia had a history of coronary artery disease or heart failure. The clinical evidence indicated that the use of Avandia in these patients may increase cardiovascular risk. Since the meta-analysis was released in May, Prime has seen a 58 percent decline in Avandia utilization.

"Prime has made this decision after a thorough analysis of the clinical literature examining the safety and efficacy of Avandia. Prime's National P&T Committee is committed to ensuring the safety and quality of Prime's formulary medications," stated Craig Mattson, Prime's Senior Director of Drug Technology Assessment and Formulary Development. "Prime takes drug safety warnings very seriously and our primary concern is the safety of our members."

Prime is committed to communicatin
'/>"/>

SOURCE Prime Therapeutics LLC
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2

Related medicine news :

1. More proof needed of safety and quality of electronic personal health records
2. Back to School Means Backpack Safety
3. Seniors Need a Safety Plan in Face of Disasters
4. New Survey Shows Americans are Still Concerned About Food Safety, Yet Still Not Smart About What They Like to Eat
5. National Patient Safety Foundation Partners with Vocera Communications
6. PA Governors Occupational Safety and Health Conference Still Accepting Registrations
7. QI projects may -- or may not -- improve patient safety and outcomes
8. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
9. Cutting Salt Wont Affect Foods Safety
10. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
11. The Risk Management and Patient Safety Institute Announces Annual Health Care Risk Conference Dates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)... new three-drug combination has shown in a phase 1/2 ... regimen" in the treatment of patients newly diagnosed with ... bone marrow, say researchers from Dana-Farber Cancer Institute. , ... the 66 patients treated with the drug combination in ... good partial response rate" in the phase 2 population, ...
(Date:12/5/2009)... of Blood Cancer Is Most Challenging-- ,, ... have identified specific genes, dubbed partner genes, that fuse ... leukemia in infants. By more accurately defining specific partner ... benefit from particular treatments. ,, Oncologists also aim ...
(Date:12/5/2009)... companies develop and test their cleaning processes. The technology available to ... and solve problems for customers relating to cleaning parts, process development, ... ... Midbrook, Inc , a Jackson, MI-based company, is home to ...
(Date:12/4/2009)... Medical Systems (NYSE: VAR ) announced today that ... Meeting of Stockholders for February 11, 2010 with a record ... at the Crowne Plaza Cabana Hotel, 4290 El Camino Real, ... will be webcast by Thomson Financial and can be accessed ...
(Date:12/4/2009)... Allied World Assurance,Company Holdings, Ltd (NYSE: ... Executive Officer, and Jack Sennott, Executive Vice,President and Chief ... Sachs U.S. Financial Services Conference being held at the ... December 8, 2009. ,, About ...
Breaking Medicine News(10 mins):Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2
... MD, offers tips to minimize riskACL tears in girls ... "Exercise and sports participation is a double-edge sword," ... Packard Children,s Hospital at Stanford . "We want ... have an obesity crisis. Yet you can have too ...
... March 3 Thoratec Corporation,(Nasdaq: THOR ), ... save, support and restore failing hearts, said today that ... Institutional Investors,Conference on Monday, March 9. , ... financial officer, will,provide an update on the company, beginning ...
... Evidence-Based Care Guidelines will be used to Combat Waste ... a permanent Recovery Audit Contractor (RAC) for the Centers ... five-year license agreement with Milliman Care Guidelines (R). ... content and software to review Medicare claims. HDI is ...
... /PRNewswire-Asia/ -- , Tigermed ... in China, and Qiming Venture, a premier venture ... asset injection to MacroStat, the unique CRO in,China ... The,union between the two top CROs will significantly ...
... N.C., March 3 MedCath Corporation (Nasdaq: ... a presentation at the Raymond James & Associates 30th ... JW Marriott Grande Lakes in Orlando, Florida. MedCath,s senior ... at 1:40 pm Eastern time. The presentation will ...
... Inc. today announced the addition of Andrew T. ... addition increases board membership to 4.(Logo: http://www.newscom.com/cgi-bin/prnh/20070206/CLTU213LOGO ... of the Medical Solutions Fund of Siemens Venture ... Prior to joining Siemens Venture Capital, he ...
Other Medicine News:Health News:Kids' 'Overuse' Sports Injuries Are on the Rise 2Health News:Recovery Audit Contractor HealthDataInsights Licenses Milliman Care Guidelines(R) 2Health News:Recovery Audit Contractor HealthDataInsights Licenses Milliman Care Guidelines(R) 3Health News:Tigermed and Qiming Venture Grant Asset Injection to MacroStat 2Health News:CorNova Announces Addition of Andrew T. Jay, D.M.D., M.B.A., to its Board of Directors 2
(Date:12/4/2009)... Dec. 4 Drs. Neal Shore and E. David ... the additional analysis of secondary end points of biochemical ... FIRMAGON® (monthly degarelix for injection) or monthly leuprolide in ... Prostate cancer patients who received FIRMAGON 240/80 mg/month ...
(Date:12/4/2009)... AstraZeneca (NYSE: AZN ) today announced that ... once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tablets as ... Depressive Disorder (MDD). SEROQUEL XR is the only medication ... both major depressive disorder as adjunctive therapy and acute ...
(Date:12/3/2009)... NEW YORK, Dec. 3 Guidepoint Global, LLC , ... their Sleep Apnea Tracker, a monthly longitudinal data release that ... Sleep Apnea market. ,, The Sleep Apnea Tracker captures ... sold in the United States from 15 different equipment providers ...
Breaking Medicine Technology:Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Apollo Health Street Collaborates with Client to Develop a CCHIT Certified 08 Ambulatory EMR 48571 1Apollo Health Street Collaborates with Client to Develop a CCHIT Certified 08 Ambulatory EMR 48571 2Norman Brinker Honored With 2009 Methodist Health System Folsom Leadership Award 48569 1Norman Brinker Honored With 2009 Methodist Health System Folsom Leadership Award 48569 2Norman Brinker Honored With 2009 Methodist Health System Folsom Leadership Award 48569 3Norman Brinker Honored With 2009 Methodist Health System Folsom Leadership Award 48569 4Industry Partners Step Up To Help Blood Cancer Patients 48567 1Industry Partners Step Up To Help Blood Cancer Patients 48567 2
... vitro microbiology and proof of concept in topical ... March 2007 - Arpida Ltd.,(SWX: ARPN) today announced ... against a large panel of,clinical isolates, including those ... of AR-2474 were found,to be highly effective in ...
... Texas, March 8, 2007--The World Health Organization,has ... cases are rising in,Pakistan. , So is ... constantly,claim, the pharmaceutical industry is denying important ... According to London’s Guardian,newspaper, “parents of ...
Other Medicine Technology:Arpida adds novel antibiotic AR-2474 to its preclinical pipeline 2Arpida adds novel antibiotic AR-2474 to its preclinical pipeline 3Why Is Polio Spreading in Pakistan? 2
EC+ Extra Care Bariatric Bed...
... Excel Care ES bed is especially designed ... empowered, while protecting the caregivers who manage them. ... the most routine tasks pulling up in ... to caregivers and disheartening for patients. Excel Care ...
... Disposable Prefilled 28%-100% FIO 2 500ML 0.45% ... nebulizers provide unmatched performance and ease of use. ... adjustable from 28% to 100% FIO 2 . ... water for inhalation, USP; 0.45% sodium chloride inhalation, ...
... Nebulizer Disposable Prefilled 28%-100% FIO 2 ... ,Our prefilled nebulizers provide unmatched performance and ... cool high-output aerosols adjustable from 28% to 100% ... of solutions: sterile water for inhalation, USP; 0.45% ...
Medicine Products: